Anti-GM-CSF Monoclonal Antibody 400mg
BiologicalAnti-GM-CSF Monoclonal Antibody 400mg
NCT Number: NCT01603277
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
Looking for future studies?
Notify Me16 year–75 year
All sexes
Interventional
Phase 2
Cairns, Queensland, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Anti-GM-CSF Monoclonal Antibody 400mg
Normal Saline
Time frame: Baseline to Week 24
Time frame: Week 24
Time frame: Week 24
Time frame: Week 24
Humanigen, Inc.
Industry
A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Acronym: KB003-04
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07191535
Asthma, Asthma (Diagnosis)
View Trial DetailsNCT06422663
Moderate-to-Severe Asthma
Baoding, China
View Trial DetailsNCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial DetailsNCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial Details